Home › Trials › NCT06245837

Examining treatment patterns and outcomes in non-small-cell lung cancer patients

Multicenter, Non-interventional, Observational Study of Treatment and Biomarker Testing Patterns, Treatment Outcomes in Advanced/Metastatic NSCLC With and Without Actionable Genomic Alterations in Routine Clinical Practice in Russia

Observational AstraZeneca · NCT06245837

This study looks at how different treatments work for adults with non-small-cell lung cancer and whether their genetic makeup affects their outcomes.

Quick facts

Study typeObservational
Enrollment1500 (estimated)
SexAll
SponsorAstraZeneca Industry-sponsored
Locations21 sites (Arkhangelsk and 20 other locations)
Trial IDNCT06245837 on ClinicalTrials.gov

What this trial studies

This observational study aims to analyze treatment and biomarker testing patterns in approximately 1500 adult patients diagnosed with non-small-cell lung cancer (NSCLC) across 20 oncological centers in Russia. The study will focus on patients with and without actionable genomic alterations, collecting data on their treatment outcomes and systemic therapy history from January 2022 to January 2025. By utilizing a representative sample from various regions, the study seeks to provide insights into the effectiveness of current treatment strategies for NSCLC.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with confirmed NSCLC, either locally advanced or metastatic, and with available treatment history.

Not a fit: Patients currently participating in clinical trials or with another cancer diagnosis within the past five years may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of treatment outcomes and inform better management strategies for NSCLC patients.

How similar studies have performed: While this study focuses on a specific population and treatment patterns, similar observational studies have shown success in identifying effective treatment strategies in cancer care.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Morphologically confirmed NSCLC with or without actionable genomic alterations (AGA, i.e. EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, ERBB2 (HER2), or KRAS)
2. Age ≥18 years at the time of NSCLC diagnosis;
3. Locally advanced or metastatic disease defined as incident stage IIIB/IIIC/IV NSCLC or stage I-IIIA then progressed to stage IIIB-IV disease and not eligible for curative-intent treatment (the date of progression is included in the database);
4. Available data on at least one line of systemic therapy for advanced/metastatic disease within the period since January 2022 until January 2025;
5. Patients may be alive or deceased at the time of medical record abstraction

Exclusion Criteria:

1. Patients participated or participating in clinical trials or any early access program within period since the index date until the end of study period;
2. Diagnosis of another cancer (except for melanoma/skin cancer) at or within 5 years prior to NSCLC diagnosis or any ongoing systemic anti-cancer therapy regimen at the time of NSCLC diagnosis

Where this trial is running

Arkhangelsk and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Non-small-cell Lung Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.